Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Insights: "PemCab Trial - Cabozantinib + Pembro as 1L Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma"
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Rohit Jain
By
Insights from 2024 ASCO® GU Annual Meeting
FEATURING
Rohit Jain
Login to view comments.
Click here to Login